|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 36
Zeitschriftenartikel
Sommerhäuser, G.; Kurreck, A.; Stintzing, S.; Heinemann, V.; Fischer von Weikersthal, L.; Dechow, T.; Kaiser, F.; Karthaus, M.; Schwaner, I.; Fuchs, M.; König, A.; Roderburg, C.; Hoyer, I.; Quante, M.; Kiani, A.; Fruehauf, S.; Müller, L.; Reinacher-Schick, A.; Ettrich, T. J.; Stahler, A. und Modest, D. P.
(2022):
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
In: BMC Cancer, Bd. 22, Nr. 1, 820
Holch, J. W.; Held, S.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Einem, J. C. von; Michl, M. und Heinemann, V
(2020):
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
In: Annals of Oncology, Bd. 31, Nr. 1: S. 72-78
Kurreck, A.; Geissler, M.; Martens, U. M.; Riera-Knorrenschild, J.; Greeve, J.; Florschütz, A.; Wessendorf, S.; Ettrich, T.; Kanzler, S.; Nörenberg, D.; Seidensticker, M.; Held, S.; Buechner-Steudel, P.; Atzpodien, J.; Heinemann, V.; Stintzing, S.; Seufferlein, T.; Tannapfel, A.; Reinacher-Schick, A. C. und Modest, D. P.
(2020):
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
In: Journal of Cancer Research and Clinical Oncology, Bd. 146, Nr. 10: S. 2681-2691
Stintzing, S.; Wirapati, P.; Lenz, H. J.; Neureiter, D.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Moehler, M.; Scheithauer, W.; Held, S.; Modest, D. P.; Jung, A.; Kirchner, T.; Aderka, D.; Tejpar, S. und Heinemann, V
(2019):
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 30, Nr. 11: S. 1796-1803
Sebio, A.; Stintzing, S.; Heinemann, V.; Sunakawa, Y.; Zhang, W.; Ichikawa, W.; Tsuji, A.; Takahashi, T.; Parek, A.; Yang, D.; Cao, S.; Ning, Y.; Stremitzer, S.; Matsusaka, S.; Okazaki, S.; Barzi, A.; Berger, M. D. und Lenz, H-J
(2018):
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
In: Pharmacogenomics Journal, Bd. 18, Nr. 1: S. 43-48
Modest, D. P.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Stintzing, S.; Modest, H. I.; Held, S.; Folprecht, G.; Heinemann, V. und Neumann, U. P.
(2017):
Central evaluation for surgical treatment options in FIRE-3-updated results and impact on overall survival.
In: Oncology Research and Treatment, Bd. 40: S. 122
Stintzing, S.; Miller-Phillips, L.; Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jagenburg, A.; Kirchner, T.; Jung, A. und Heinemann, V.
(2017):
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
In: European Journal of Cancer, Bd. 79: S. 50-60
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Stintzing, S.; Price, B.; Knight, L.; McCavigan, A.; Walker, S.; Harkin, P.; Kennedy, R.; Neureiter, D.; Held, S.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 28
Holch, J. W.; Stintzing, S.; Held, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Kirchner, T.; Einem, J. C. von; Modest, D. P. und Heinemann, V.
(2017):
Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
In: Oncology Research and Treatment, Bd. 40: S. 164-165
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Bd. 40: S. 123
Berger, M. D.; Stintzing, S.; Heinemann, V.; Yang, D.; Cao, S.; Sunakawa, Y.; Ning, Y.; Matsusaka, S.; Okazaki, S.; Miyamoto, Y.; Suenaga, M.; Schirripa, M.; Soni, S.; Zhang, W.; Falcone, A.; Loupakis, F. und Lenz, H.-J.
(2017):
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
In: Annals of Oncology, Bd. 28, Nr. 11: S. 2780-2785
Modest, D. P.; Kasper, S.; Stintzing, S.; Prasnikar, N.; Müller, L.; Caca, K.; Gökkurt, E.; Fischer von Weikersthal, L.; Kopp, H.-G. und Trarbach, T.
(2016):
Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RASWT metastatic colorectal cancer.
In: Annals of Oncology, Bd. 27
Laurent-Puig, P.; Grisoni, M.-L.; Heinemann, V.; Fontaine, K.; Vazart, C.; Decaulne, V.; Rousseau, F.; Courtieu, B.; Lieabert, F.; Jung, A.; Neureiter, D.; Thiebaut, R. und Stintzing, S.
(2016):
MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial.
In: Annals of Oncology, Bd. 27
Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Hielscher, J.; Lerch, M.; Scheithauer, W.; Jagenburg, A.; Held, S.; Modest, D.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306).
In: Annals of Oncology, Bd. 27: S. 112
Stahler, A.; Stintzing, S.; Urbischek, M.; Modest, D. P.; Fischer von Weikersthal, L.; Kumbrink, J.; Heinemann, V.; Kirchner, T. und Jung, A.
(2016):
Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).
In: Annals of Oncology, Bd. 27
Neumann, U.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Folprecht, G.; Stintzing, S.; Held, S.; Heinemann, V. und Modest, D. P.
(2016):
Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) - a retrospective, central evaluation of FIRE-3.
In: Annals of Oncology, Bd. 27
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Sebio, A.; Matsusaka, S.; Zhang, W.; Yang, D.; Ning, Y.; Stremitzer, S.; Stintzing, S.; Sunakawa, Y.; Yamauchi, S.; Fujimoto, Y.; Ueno, M. und Lenz, H-J
(2016):
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
In: Pharmacogenomics Journal, Bd. 16, Nr. 4: S. 312-319
Modest, D. P.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer.
In: Oncology Research and Treatment, Bd. 39: S. 11
Sunakawa, Y.; Bekaii-Saab, T. und Stintzing, S.
(2016):
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
In: Cancer Treatment Reviews, Bd. 45: S. 97-104
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
Heinemann, V.; Stintzing, S.; Modest, D. P.; Giessen-Jung, C.; Michl, M. und Mansmann, Ulrich
(2015):
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
In: European Journal of Cancer, Bd. 51, Nr. 14: S. 1927-1936
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
Modest, D. P.; Laubender, Rüdiger P.; Stintzing, S.; Giessen, C.; Schulz, C.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial.
In: Acta Oncologica, Bd. 52, Nr. 5: S. 956-962
Modest, D. P.; Camaj, P.; Heinemann, V.; Schwarz, B.; Jung, A.; Laubender, Rüdiger P.; Gamba, S.; Haertl, C.; Stintzing, S.; Primo, S. und Bruns, C. J.
(2013):
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 6: S. 953-961
Meimarakis, G.; Angele, Martin Kurt; Conrad, C.; Schauer, R.; Weidenhagen, R.; Crispin, Alexander; Giessen, C.; Preissler, G.; Wiedemann, Max; Jauch, K. W.; Heinemann, V.; Stintzing, S.; Hatz, R. A. und Winter, H.
(2013):
Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone.
In: Langenbeck's Archives of Surgery, Bd. 398, Nr. 2: S. 265-276
Giessen, C.; Fischer von Weikersthal, L.; Laubender, Rüdiger P.; Stintzing, S.; Modest, D. P.; Schalhorn, A.; Schulz, C. und Heinemann, V.
(2013):
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
In: British Journal of Cancer BJC, Bd. 109, Nr. 6: S. 1428-1436
Giessen, C.; Graeven, U.; Laubender, Rüdiger P.; Modest, D. P.; Schulz, C.; Porschen, R.; Schmiegel, W.; Reinacher-Schick, A.; Hegewisch-Becker, S.; Stintzing, S. und Heinemann, V.
(2013):
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 24, Nr. 12: S. 3051-3055
Giessen, C.; Laubender, Rüdiger P.; Ankerst, Donna Pauler; Stintzing, S.; Modest, D. P.; Mansmann, Ulrich und Heinemann, V.
(2013):
Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in mCRC: Literature-Based Analysis from 50 Randomized First-Line Trials.
In: Clinical Cancer Research, Bd. 19, Nr. 1: S. 225-235
Giessen, C.; Laubender, Rüdiger P.; Fischer von Weikersthal, L.; Schalhorn, A.; Modest, D. P.; Stintzing, S.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial.
In: Cancer Science, Bd. 104, Nr. 6: S. 718-724
Hofheinz, R. D.; Heinemann, V.; Fischer von Weikersthal, L.; Laubender, Rüdiger P.; Gencer, D.; Burkholder, I.; Hochhaus, A. und Stintzing, S.
(2012):
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
In: British Journal of Cancer BJC, Bd. 107, Nr. 10: S. 1678-1683
Modest, D. P.; Jung, A.; Moosmann, N.; Laubender, Rüdiger P.; Giessen, C.; Schulz, C.; Haas, M.; Neumann, J.; Boeck, S.; Kirchner, T.; Heinemann, V. und Stintzing, S.
(2012):
The influence of KRAS- and BRAF-mutations on the efficacy of cetuximab-based 1st-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104 -trial.
In: International Journal of Cancer, Bd. 131, Nr. 4: S. 980-986
Modest, D. P.; Reinacher-Schick, A.; Stintzing, S.; Giessen, C.; Tannapfel, A.; Laubender, Rüdiger P.; Brodowicz, T.; Knittelfelder, R.; Vrbanec, D.; Schmiegel, W.; Heinemann, V. und Zielinski, C. C.
(2012):
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
In: Anticancer Drugs, Bd. 23, Nr. 6: S. 666-673
Modest, D. P.; Stintzing, S.; Laubender, Rüdiger P.; Neumann, J.; Jung, A.; Giessen, C.; Haas, M.; Aubele, P.; Schulz, C.; Boeck, S.; Stemmler, H. J.; Kirchner, T. und Heinemann, V.
(2011):
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
In: Anticancer Drugs, Bd. 22, Nr. 9: S. 913-918
Giessen, C.; Stintzing, S.; Laubender, Rüdiger P.; Ankerst, Donna Pauler; Schulz, C.; Moosmann, N.; Modest, D. P.; Schalhorn, A.; Fischer von Weikersthal, L. und Heinemann, V.
(2011):
Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer.
In: Clinical Colorectal Cancer, Bd. 10, Nr. 4: S. 317-324